ArticleNature2019
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
15.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 218 citations in OpenAlex.
- NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition.Molecular cancer therapeutics · 2026Article
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- Article
- Review
- The Tryptophan Paradox: From Microbiome-Mediated Homeostasis to Tumor-Driven Immune Escape.International journal of molecular sciences · 2026Review
- Enhanced Antitumor Response in Breast Cancer via Parthanatos Activation Mediated by the Synergistic Effect of Etoposide and Resveratrol.Current issues in molecular biology · 2026Article
- Nicotinamide salvage is required for proliferation and sustaining self-renewal in undifferentiated embryonic stem cells.Stem cells (Dayton, Ohio) · 2026Article
- Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy.Current oncology reports · 2026Review
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
- NAPRT-mediated deamidated NAD biosynthesis enhances colon tissue resiliency and suppresses tumorigenesis.Nature communications · 2026Article
- Glutamine metabolism and its roles in tumor radiotherapy by regulating DNA damage repair.Frontiers in cell and developmental biology · 2026Review
- Case Report: Long-term remission of metastatic pancreatic ductal adenocarcinoma after surgery and high-dose nicotinamide supplementation.Frontiers in oncology · 2026Article
- RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination.Communications biology · 2025Article
- Inhibition of TRAF3IP2 Modulates NAMPT and NAD Metabolism in Glioblastoma.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Cancer progression through the lens of age-induced metabolic reprogramming.Nature reviews. Cancer · 2025Review
- Deciphering enemy tactics - the narrow path to an optimal anti-cancer strategy targeting the Warburg effect.Pharmacological reports : PR · 2025Review
- Apoptotic Bodies Restore NAD and Mitochondrial Homeostasis in Fibroblasts.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment.Cell communication and signaling : CCS · 2025Article
- NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.Blood advances · 2025Article
- Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.Cell death discovery · 2025Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 4 institutions in 2 countries.
Sudhir ChowdhryLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Ciro Zanca *Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Utkrisht Rajkumar *Department of Computer Science and Engineering, University of California at San Diego, La Jolla, CA, USA.
Tomoyuki KogaLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Yarui DiaoDepartment of Cell Biology, Regeneration Next Initiative, Duke University School of Medicine, Durham, NC, USA.
Ramya RaviramLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Feng LiuNational Research Center for Translational Medicine, Ruijin Hospital, Shanghai, China.
Kristen TurnerLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Huijun YangLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Elizabeth BrunkLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Junfeng BiLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Frank FurnariLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Vineet BafnaDepartment of Computer Science and Engineering, University of California at San Diego, La Jolla, CA, USA.
Bing RenLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.
Paul S MischelLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA. pmischel@ucsd.edu.
Ludwig Cancer Research · USUniversity of California, San Diego · USDuke University · USRuijin Hospital · CN
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MUCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3MGenotypic Interactions in Brain Cancer HeterogeneityR01NS080939 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FURNARI, FRANK · 2012 to 2022
$3.5MThe role of mTORC2 in reprogramming cancer cell metabolismR01NS073831 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MISCHEL, PAUL S · 2011 to 2020
$3.4MIntegrated ligand and target discovery by chemical proteomics for glioblastoma treatment.R01CA238249 · NCI · STANFORD UNIVERSITY · PI CRAVATT, BENJAMIN F, MISCHEL, PAUL S · 2021 to 2025
$3.3MComputational methods for detecting patterns of complex genomic variationR01GM114362 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Vineet Bafna · 2016 to 2026
$3.1MGenotypic Interactions in Brain Cancer HeterogeneityR56NS080939 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FURNARI, FRANK · 2023 to 2023
$537kNCI NIH HHS P30 CA014236NCI NIH HHS R01 CA238249NCI NIH HHS T32 CA121938NIGMS NIH HHS R01 GM114362NIH HHS CA121938NIH HHS GM114362NIH HHS NS73831NIH HHS NS80939NIH HHS T32 CA009253NINDS NIH HHS R01 NS073831NINDS NIH HHS R01 NS080939NINDS NIH HHS R56 NS080939
Abstract
Precision oncology hinges on linking tumour genotype with molecularly targeted drugs
Indexed as
Gene AmplificationAnimalsCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell DeathCell Line, TumorCytokinesEnhancer Elements, GeneticEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMiceNADNeoplasmsNicotinamide PhosphoribosyltransferasePentosyltransferasesCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCytokinesNADNADSYN1 protein, humanNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humannicotinate phosphoribosyltransferaseNMRK1 protein, humanPentosyltransferasesPhosphotransferases (Alcohol Group Acceptor)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.